Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
if this is to rise in PPS you need more volume and (in my view) more shares.
82 milly shares should be locked up! Why would anyone sell when the 200,000 % profit DIVI is just down the road? you would be insane crazy to sell.
I see no share dump that's a good sign, however you would need major volume for dilution and the that cannot happen with 82 milly shares, unless of course.....84 trades 4,241,304 BUYS 1,252,650, SELLS
03/28/2013
PDF
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NASDAQ: CYTX) received US Patent No. 8,404,229 (the ‘229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs). The ‘229 patent covers treatment of a broad range of renal disorders, including acute kidney disease (AKD) and chronic kidney disease (CKD). The ‘229 patent also covers multiple means of delivering the ADRCs, including
Insider trading UP
volume up for last month
Feb 27, 2013 JORDEN DAVID EMERSON
Director direct Buy 0.53 4,400
Feb 26, 2013 JORDEN DAVID EMERSON
Director direct Buy 0.52 20,600
Feb 22, 2013 KENT RICHARD S
Director indirect Buy 0.55 963,637
Feb 22, 2013 ALDAGEN HOLDINGS, LLC
Beneficial Owner (10%) indirect Buy 0.55 281,819
Feb 22, 2013 ROSENDALE MARTIN P
Officer direct Buy 0.53 20,000
Feb 22, 2013 JORDEN DAVID EMERSON
Director direct Buy 0.53 20,000
Feb 21, 2013 JORDEN DAVID EMERSON
Director direct Buy 0.53 30,000
Feb 19, 2013 DEL GUERCIO JOSEPH
Director indirect Buy 0.55 509,091
Feb 13, 2013 ALDAGEN HOLDINGS, LLC
Beneficial Owner (10%) direct Dispositio
FROM OTC
Shares Outstanding 777,202,019 a/o Nov 08, 2012
Float 540,026,238 a/o Nov 08, 2012
Authorized Shares 4,000,000,000 a/o Oct 16, 2012
Call me suspicious but they have no filings since Nov 15, 2012 (NT 10-Q late filing)
And here is the last 10-Q from 8/20/2012
On April 24, 2012 the Board of Directors authorized the Company to amend the articles of incorporation to increase the number of authorized common stock of the Company from 10,000,000 to 200,000,000 shares,
I like the look of this company,they do good stuff, but it looks like a setup to dump and R/S am I wrong?
Thank You DBS!
Fine GLTY
It is true that it is news, but is it accurate news time will tell.
IT is a 294,995.00% yield just a tad high for a company trading at .0006
LOGIC If its too good to be true, it probably is.
Cytomedix Announces Centers for Medicare & Medicaid Services (CMS) Issuance Of Reimbursement Coding for Autologous PRP in Chronic Non-Healing Wounds
Assignment of HCPCS Code Establishes Reimbursement Mechanism for Physicians and Other Healthcare Providers
CYTOMEDIX REPORTS 2012 FOURTH QUARTER AND FULL YEAR FINANCIAL
RESULTS
Conference Call Scheduled for Tuesday March 19th at 8:30am Eastern Time
GAITHERSBURG, Maryland – March 18, 2013 – Cytomedix, Inc. (OTCQX: CMXI), a
leading developer of biologically active regenerative therapies, today reported financial
results for the three and twelve months ended December 31, 2012.
Fourth Quarter 2012 Financial Highlights (all comparisons are with the 2011
fourth quarter)
• Product revenue of $2.0 million compared with $1.6 million, an increase of 27%.
• Consolidated revenue of $2.1 million compared with $3.0 million, a decrease of
29%.
• Net loss to common stockholders of $3.8 million, or $0.04 per share. This
compares with a net income of $0.8 million, or $0.02 per share in the prior year.
• Cash and cash equivalents of approximately $2.6 million at December 31, 2012.
In February 2013, the Company received $9.5 million of gross proceeds at
closing as part of a comprehensive financing plan.
Fiscal Year 2012 Financial Highlights
• Consolidated revenue of $10.6 million compared with $7.2 million in 2011.
• Product revenue increased 23% year over year to $7.2 million from $5.9 million
in 2011.
• Net loss to common stockholders for the year of $19.8 million, or ($0.24) per
share, compared with $3.9 million, or ($0.08) per share in 2011.
Clinical and Corporate Highlights for the Fourth Quarter and Recent Weeks
• Earlier today, the Company announced that the Centers for Medicare & Medicaid
Services (CMS) has issued coding and reimbursement claims instructions for
autologous PRP in non-healing chronic wounds.
• On March 1
st, 2012 CMS granted formal approval of the protocols for AutoloGel
under Coverage with Evidence Development (CED).
• A comprehensive 2013 financing was executed to raise a total of up to $27.5
million, including $9.5 million in initial gross proceeds, comprised of a registered
equity offering, a senior secured term loan and a committed equity facility.
• The Angel®
Concentrated Platelet Rich Plasma (cPRP) System was approved for
marketing in Australia.
• CE Mark in Europe was granted for the Angel cPRP System for processing blood
and bone marrow aspirate.
• The FDA granted approval for Angel for processing bone marrow aspirate. This
approval significantly expands the orthobiologic commercial opportunity for the
Angel system, increasing the addressable market to include the 400,000 spinal
fusion procedures performed each year in the U.S.• A Phase 2 clinical study, in collaboration with the NIH, was announced for ALD-
301 (Bright Cells) in patients with an intermittent claudication indication
associated with peripheral artery disease.
Management Discussion
“We accomplished many of our growth objectives in 2012,” said Martin Rosendale,
Chief Executive Officer of Cytomedix. “We were especially pleased by strong doubledigit growth in Angel and AutoloGel sales. We have now placed more than 500 Angel
Systems on a worldwide basis. Nearly 40,000 patients are currently being treated with
the Angel System on an annualized basis.”
“A significant milestone in 2012 was the announcement that CMS had agreed to
reimburse AutoloGel under the CED program. We were delighted to report earlier in
this month that CMS has formally approved the clinical outcomes in the protocols we
had submitted in response to the National Coverage Determination (NCD) memo. This
means that clinicians can now use AutoloGel to treat Medicare patients with chronic
wounds and receive reimbursement. This should have a significantly positive impact on
AutoloGel revenues in 2013. Finally, we announced earlier today that CMS has issued
coding and reimbursement instructions to its regional contractors. Consequently, we
expect to begin treating Medicare beneficiaries with AutoloGel shortly and recording
revenues for AutoloGel as a covered product.”
“Our Bright Cell technology pipeline continues to advance. We are enrolling patients in
the RECOVER-Stroke Trial with ALD-401. This clinical trial is currently enrolling at 9
sites and we believe it’s on track to complete enrollment by the end of the year. We also
announced late last year the signing of an agreement with NIH to collaborate on a
Phase 2 clinical study with ALD-301 in patients with intermittent claudication, caused by
peripheral arterial disease (PAD), This is the first randomized clinical trial that will look
at the benefits of autologous stem cell therapy in this patient population.”
“We announced last month a $27.5 million comprehensive financing, which includes an
equity raise, a tranched senior secured term loan facility, and a committed equity facility.
We received approximately $9.5 million in initial gross proceeds with commitments for
up to an additional $18 million. This capital infusion provides us with the necessary
capital to fund our priority activities in 2013 which include the launch of AutoloGel under
CED, sales expansion for the Angel cPRP System, business development and
partnering activities, and completion of the RECOVER-Stroke phase 2 study
How long has IFIXQ been in BK ???
This is from bloomberg
Executive Profile*
Florin Lacatus
Chief Executive Officer, President and Director, Zupintra Corporation, Inc
Age 41 --
Background*
Florin Lacatus has been Chief Executive Officer and President of Zupintra Corporation, Inc. since May 2009. Mr. Lacatus has 38 years of experience in the logistics Industry in Europe. Mr. Lacatus is a computer engineer with 11 years of experience in complex billing and data mining architectures. He served as Vice President of Business Development for MLP Radov. Mr. Lacatus has been a Director of Zupintra Corporation, Inc. since May 2009.
no Education data no affiliations data
click on this for link
insert-text-here
It has to be a scam to dump shares --
YAWN $SNDY tells us whats happening End of world as we know it.....
4 AM and no coffee. I was thinking of selling intellectual property which is different. From what I have seen at CCAJ there is none of that.
However looking back a month or 2 I read, I do not say I know for sure BUT as I wrote Tony Owned his company merged With CCAJ and backed out on a technicality and somehow got to keep CCAJ as I mentioned Litigation is involved. Look at my old posts and more importantly the posts that replied. Tony is supposed to have very good Legal representation for this very matter. Maybe someday it will be worth something,but not just now.
I'm pretty sure assets can be sold/transferred and the shell left BUT they would (I think) have to inform the investors which apparently they did. This one is strange Tony merges his company with shell then finds flaw in contract, withdraws and gets to keep the shell. (there is I believe litigation involved) Someday something profitable may come of this.
Might there be a bounce here as the not talls cover??
somebodys buying this swill
"His silence tells you all you need to know."
my hearing ain't that good. GOOOOOO $PRPM
my mistake still 1.3 billion left to dump
If AUMY does not RS I B shocked
I'm not trying to YAK ya but has anything materially changed here?
Did not "Tony" grab this shell from the recended merger? "Tony"has (or had ) ongoing operations down there(tile store/ manufacture see my posts)The shell is empty last I heard. Was it all a fraud?
SNDY AHEAD OF SCHEDULE 4 WEEKS OR LESS
Yessss 4 weeks (or less) from NOW
Solos Endoscopy completed the Stage 1 Audit with TÜV SÜD America on Tuesday, February
26, 2013 (its been 4 weeks)
4 weeks or less til stage 2 completion from NOW
A few weeks or less and KABOOMAGE
Excellent point Vertical
Thanks Stately,
Read a recent news paper dude HO HUM
I mean to say SIX WEEKS=CE MARK JACK
You got me
Thats two words alright LOL
I did not credit Pennylanepam sticky
The truth about the post Audit1
As last week (see my posts) I had to go the extra mile again and contacted Sarah from Emergo group to verify, how many companies actually would need 6 months to get Audit 2 done. She said that AUdit 2 is always done in no longer than 8 weeks from Audit 1
you say not to believe anything they say now you quote them
Any news on the lawsuit??? sorry I did not mean to reply beginners
CE in 6 weeks GO $SNDY